Invizius Announces Appointment of Peter Stenvinkel, Professor of Nephrology at Karolinska Institutet, to the Clinical Advisory Board

World leading expert and key opinion leader in nephrology

Glasgow, Scotland, 13 July 2022 – Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, is pleased to announce the appointment of Professor Peter Stenvinkel to its Clinical Advisory Board. Professor Stenvinkel is a world-renowned expert senior lecturer at Karolinska University Hospital and Professor of Nephrology at Karolinska Institutet (KI), Stockholm, Sweden.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH